Please check your internet connection and try again.
# Hyaluronic acid
## Overview
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found in connective tissues, synovial fluid, and the extracellular matrix. Exogenous forms are utilized as viscosupplements for joints, ophthalmic surgical aids, dermal fillers, and topical moisturizing agents.
## Primary Indications
* **Osteoarthritis (OA):** Pain management in patients who failed conservative therapy (e.g., knee, hip, shoulder).
* **Ophthalmology:** Surgical aid in cataract extraction, IOL implantation, and corneal surgery.
* **Dermatology/Aesthetics:** Facial soft tissue augmentation and skin hydration.
## Adult Dosing
* **Osteoarthritis (Intra-articular):**
* **Hylan G-F 20 (Synvisc):** 2 mL (16 mg) into knee joint weekly for 3 weeks.
* **Sodium Hyaluronate (Euflexxa):** 2 mL (20 mg) into knee joint weekly for 3 weeks.
* **Cross-linked (Synvisc-One):** 6 mL (48 mg) into knee joint as a single injection.
* *Note: Dosing frequency and volume are highly specific to the product brand and local protocol.*
## Pediatric Dosing
* **Safety/Efficacy:** Not established for intra-articular use in children. Use in pediatric dermatology or ophthalmology should follow site-specific institutional guidelines or specialist oversight.
## Dose Adjustments
* **Renal/Hepatic:** Not required; HA is locally acting and degraded by hyaluronidase throughout the body.
## Contraindications
* Known hypersensitivity to hyaluronate preparations.
* Known hypersensitivity to avian proteins (for avian-derived products).
* Active joint infection, severe joint inflammation, or active skin disease at the injection site.
## Adverse Effects
* **Intra-articular injection:** Transient pain, joint swelling/effusion, stiffness at the injection site, or localized arthralgia.
* **General:** Rare systemic hypersensitivity or pseudo-septic arthritis (pseudosepsis).
* **Aesthetic/Topical:** Bruising, erythema, nodules, or granuloma formation at the injection site.
## Key Drug Interactions
* **Quaternary Ammonium Salts:** Incompatible with hyaluronic acid in ophthalmic solutions (precipitation).
* **Disinfectants:** Do not use skin disinfectants containing quaternary ammonium salts for joint preparation, as they may precipitate HA.
## Monitoring
* **Clinical:** Monitor for signs of local infection (heat, redness, fever) post-injection.
* **Efficacy:** Assess pain reduction and range of motion at follow-up visits.
## Clinical Pearls
* **Pseudosepsis:** Patients may present with acute, severe pain and swelling 24–72 hours post-injection. This is an immune reaction, not an infection. Aspirate joint fluid to rule out bacterial septic arthritis.
* **Efficacy Lag:** Pain relief is not immediate; patients often expect results within 24 hours, but maximum benefit may take several weeks to manifest.
* **Product Specificity:** Cross-linked products (Hylan) have a longer half-life than non-cross-linked sodium hyaluronate. Always confirm the specific brand’s storage and administration requirements.
***
**Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Dosing and administration protocols vary by product manufacturer and individual institutional policies. Always verify the most current prescribing information (package insert) and clinical guidelines before prescribing or administering.
